PEA (palmitoylethanolamide) — an endocannabinoid-like compound for pain (table)
PEA: tabela, ile, kiedy i jak. Przewodnik u Bucha.
Palmitoylethanolamide (PEA) is a substance that your own body produces in response to pain and inflammation — a type of endogenous "fire extinguisher" for the nervous system. The Nobel Prize in Physiology and Medicine for 2021 (for the discovery of temperature and touch receptors) indirectly fits into the same biology of pain, in which PEA plays a significant role. A meta-analysis of 10 randomized clinical trials published in Pain Physician (2016) showed that PEA supplementation significantly reduces neuropathic pain compared to control (Pain Physician, 2016). This article explains how PEA works, how to dose it, and how it differs from CBD.
KEY INFORMATION
• PEA (palmitoylethanolamide) is an endogenous amide lipid that acts as a natural pain and inflammation modulator.
• A meta-analysis of 10 clinical studies confirmed the effectiveness of PEA in neuropathic pain (Pain Physician, 2016).
• Standard protocol: 1200 mg/day (2 × 600 mg) for 6–8 weeks, then 600 mg/day for maintenance.
• The ultramicronized form (um-PEA) has significantly higher bioavailability than the standard powder.
• PEA and CBD have complementary mechanisms — the combination is being clinically studied for synergistic effects.
Czym jest PEA i dlaczego jest „endokannabinoidopodobny”?
PEA belongs to the family of N-acylethanolamines (NAE) — the same family as anandamide, one of the main endocannabinoids. Although PEA itself does not strongly bind to CB1 or CB2 receptors, it acts on the endocannabinoid-like system through other mechanisms. The main molecular target is the nuclear receptor PPAR-alpha (peroxisome proliferator-activated receptor), which regulates the expression of genes involved in inflammation and pain (PMC6326490).
PEA also activates the GPR55 receptor and modulates ion channels (TRPV1 through the "entourage" mechanism with other endocannabinoids). The end result is: reduced degranulation of mast cells at the site of injury or inflammation, decreased release of pro-inflammatory cytokines, and reduced hypersensitivity of peripheral nerves. This is why PEA is particularly effective in neuropathic pain — where traditional pain medications often fail.
The body produces PEA "on demand" — locally, in tissues under stress or inflammation. In chronic pain and prolonged inflammation, endogenous production may be insufficient. Supplementing with external PEA compensates for this deficiency and maintains the protective effect.
PEA Dosage Table
The key difference between forms of PEA has significant practical implications. Standard PEA (crystals with a diameter of ~20 µm) is poorly absorbed through the lymphatic system. Micronized PEA (m-PEA, particles ~10 µm) and ultramicronized PEA (um-PEA, particles ~0.5–3 µm) have progressively better bioavailability. Comparative studies indicate that um-PEA at half the dose of standard PEA provides similar or better plasma concentrations (PMC6326490).
| Indication | Dose (m-PEA or um-PEA) | Duration | Scheme / notes |
|---|---|---|---|
| Neuropathic pain (intensive phase) | 600 mg 2× daily (1200 mg/day) | 6–8 weeks | With meals; morning and evening |
| Neuropathic pain (maintenance) | 600 mg 1× daily | For up to 6 months or cyclically | After evaluating effects after 8 weeks |
| Sciatica / back pain | 600 mg 2× daily | 4–6 weeks | Protocol used in the study by Guida et al. (2010) |
| Fibromyalgia | 300–600 mg 2× daily | Min. 3 months | Effects are slower than in neuropathic pain |
| Inflammatory conditions (preventively) | 300–400 mg/day | 4–8 weeks, cyclically | Lower doses for mild ailments |
| um-PEA (ultramicronized) | 300 mg 2× daily (600 mg/day) | As above | Higher bioavailability — effective half dose of m-PEA |
Price update: May 4, 2026
PEA effects appear gradually. Most clinical studies report the first measurable effects after 2–4 weeks of regular use, with full effect after 6–8 weeks. This is due to the mechanism — PEA does not act like a classic painkiller (it does not block COX or opioid receptors immediately), but modulates the expression of inflammatory genes through PPAR-alpha, which takes time. Patience is more important here than with NSAIDs or paracetamol.
PEA vs CBD — similarities and differences
This question comes up very often because both compounds are described as "natural" and "endocannabinoid-like." However, the differences are significant and worth understanding when choosing a supplement.
CBD (cannabidiol) is a phytocannabinoid — derived from the Cannabis sativa plant. It acts, among other things, by modulating CB1/CB2 receptors, blocking the FAAH enzyme (which degrades anandamide), activating serotonin receptors 5-HT1A, and blocking ion channels. PEA is an endogenous substance — synthesized in human cells — and mainly acts through PPAR-alpha and GPR55, not binding strongly to CB1/CB2.
Key clinical difference: PEA has stronger clinical evidence in neuropathic pain and sciatica. CBD has more data in anxiety, epilepsy (Epidiolex), and sleep disorders. Studies on the combination of PEA+CBD show a synergistic effect ("entourage effect" internally) — together they may work stronger than either alone. This is an interesting research direction, although clinical data for the combination is still scarce (PMC6326490).
PEA in clinical studies — overview of indications with evidence
The clinical basis for PEA consists of dozens of randomized studies conducted mainly in Italy and Spain since the 2000s. In addition to the meta-analysis of neuropathic pain (2016), other specific indications are noteworthy. Sciatica: the study by Guida et al. (2010) on 636 patients showed that m-PEA at a dose of 600 mg 2× daily for 3 weeks reduced the VAS pain score by an average of 47% — a result comparable to NSAIDs, without their gastrointestinal side effects (PubMed, 2010).
Fibromyalgia is another indication with a growing body of evidence. Fibromyalgia is a condition characterized by central pain sensitization — the brain and spinal cord 'process' normal signals as painful. PEA, through the modulation of microglia (immune cells of the brain and spinal cord) via PPAR-alpha, may suppress this centrally induced sensitization. The study by Paladini et al. (2016) showed a reduction in pain and fatigue in fibromyalgia patients after 3 months of um-PEA supplementation.
Arthritis and joint pain is an area where PEA is relatively underappreciated despite a logical mechanism. Mast cells are abundantly present in the synovial membrane of joints and play a role in local joint inflammation. PEA stabilizes mast cells and inhibits their degranulation — which may reduce local inflammation in the joint. Animal model studies are promising; clinical studies in humans with rheumatoid arthritis and osteoarthritis are still limited, but the direction is biologically justified.
How PEA affects the nervous system — neuroprotection and neuropathy
PEA is produced in the brain and spinal cord, where it plays a neuroprotective role. Preclinical studies have shown that PEA reduces neuronal damage after ischemia, protects myelin, and inhibits microglial activation — a pathophysiological mechanism underlying many neurological diseases. In the context of multiple sclerosis (MS), studies on mouse models of experimental autoimmune encephalomyelitis (EAE) have shown that PEA reduces demyelination and inflammation in the spinal cord (PMC6326490).
Diabetic neuropathy is one of the most important clinical applications of PEA. Pain, numbness, and burning in the feet and hands of diabetics result from peripheral nerve damage due to glycation and oxidative stress. PEA addresses the inflammatory and mitochondrial components of neuropathy. A randomized study (Schifilliti et al., 2014) on 40 diabetics with neuropathy showed a significant reduction in pain and improvement in nerve function after 8 weeks of um-PEA 600 mg/day. Neuropathy is an indication where PEA can be a particularly valuable complement to conventional therapy.
Irritable bowel syndrome (IBS) and visceral pain are other areas where PEA is being studied. In the intestines, mast cells form functional connections with enteric sensory neurons and play a role in visceral hypersensitivity — a typical pain mechanism in IBS. PEA, by inhibiting the degranulation of intestinal mast cells, may reduce visceral hypersensitivity without affecting gut motility — an effect different from classical antispasmodic drugs. Preliminary clinical studies have shown a reduction in abdominal pain and an improvement in quality of life in IBS patients taking um-PEA for 8 weeks. The local mechanism — direct contact of PEA with intestinal cells after oral intake — may be an additional advantage in this case due to the weaker systemic bioavailability.
Endometriosis is one of the newer indications being studied for PEA. Pain in endometriosis has both an inflammatory component (prostaglandins and leukotrienes produced by ectopic endometrial tissue) and a neuropathic component (growing nerves within the lesions). PEA addresses both of these mechanisms. A pilot study (Cobellis et al., 2004) showed a reduction in menstrual pain in women with endometriosis using PEA. Although this is a small study, the biological justification is strong, and PEA is becoming a complementary component in endometriosis treatment protocols.
Frequently Asked Questions
How much PEA should I take daily and for how long?
The standard protocol is 600 mg twice a day (1200 mg/day) for the first 6–8 weeks, followed by a reduction to 600 mg/day for maintenance. The ultramicronized form (um-PEA) requires half this dose with similar efficacy. Always check the formulation — standard PEA has low bioavailability. A clinical meta-analysis (Pain Physician, 2016) confirmed efficacy at these doses.
What does PEA work for and is there clinical evidence?
PEA has documented clinical applications in neuropathic pain, sciatica, and fibromyalgia. A meta-analysis of 10 randomized clinical trials (2016) showed a statistically significant reduction in pain vs placebo. Mechanism: activation of PPAR-alpha (nuclear receptor), inhibition of mast cell degranulation, reduction of pro-inflammatory cytokines.
Is PEA safe and does it have side effects?
PEA is considered very safe — it is an endogenous substance produced by the body. A clinical review involving over 6000 patients did not report any serious adverse effects. The most common mild complaints are stomach discomfort at higher doses. There are no documented drug interactions, although caution is advised with prescription medications.
How does PEA differ from CBD?
PEA is an endogenous N-acylethanolamine acting through PPAR-alpha and GPR55. CBD is a phytocannabinoid modulating CB1/CB2 receptors. PEA has stronger evidence in neuropathic pain, while CBD has stronger evidence in anxiety and epilepsy. The mechanisms complement each other — the combination of PEA+CBD shows synergy in preclinical studies (PMC6326490).
When should I take PEA — in the morning or evening, with food or without?
PEA is a lipophilic substance — absorption is better with a meal containing fats. The standard regimen: the first dose with the morning meal, the second with the evening meal. The um-PEA form has better bioavailability and is acceptably absorbed without fat, but it is always optimal with food.
This article is for informational and educational purposes and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.
Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04
